海吉亞醫療(06078.HK)與控股股東組合營 設雲南省開遠解化醫院
海吉亞醫療(06078.HK)公布,全資附屬伽瑪星科技與由控股股東朱義文與其女兒朱劍喬之向上投資就擬成立合營企業訂立合營協議,設雲南省開遠解化醫院。
根據合營協議,伽瑪星科技及向上投資同意分別出資500萬元人民幣(下同)及214.29萬元,分別佔合營企業註冊資本總額的70%及30%。
伽瑪星科技及向上投資按照其各自於開遠解化醫院的舉辦人權益相同的比例成立合營企業,是開遠解化醫院進行營利性改制的一步。合營企業將為經營該營利性醫院的法律實體。
公司看好開遠市的腫瘤醫療市場潛力,並擬進一步開發開遠解化醫院腫瘤業務,以更有效為腫瘤患者提供服務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.